The identification of molecules associated with specific genomic regions of interest is required to understand the mechanisms of regulation of the functions of these regions. To enable the non-biased identification of molecules interacting with a specific genomic region of interest, we recently developed the engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP) technique. Here, we describe how to use enChIP to isolate specific genomic regions and identify the associated proteins and RNAs. First, a genomic region of interest is tagged with a transcription activator-like (TAL) protein or a clustered regularly interspaced short palindromic repeats (CRISPR) complex consisting of a catalytically inactive form of Cas9 and a guide RNA. Subsequently, the chromatin is crosslinked and fragmented by sonication. The tagged locus is then immunoprecipitated and the crosslinking is reversed. Finally, the proteins or RNAs that are associated with the isolated chromatin are subjected to mass spectrometric or RNA sequencing analyses, respectively. This approach allows the successful identification of proteins and RNAs associated with a genomic region of interest.
Introduction
The identification of molecules associated with specific genomic regions of interest is required to understand the mechanisms of regulation of genomic functions such as transcription and epigenetic regulation. Although several techniques have been developed for biochemical analysis of specific genomic regions [1] [2] [3] [4] [5] [6] [7] , they are not used widely at this stage because of their intrinsic problems such as limited application (e.g., only for high-copy number loci or loci with repeats) and too much time and efforts required.
In order to perform biochemical analysis of specific genomic regions easily, we have developed two locus-specific chromatin immunoprecipitation (ChIP) technologies, namely insertional ChIP (iChIP) [8] [9] [10] [11] [12] [13] and engineered DNA-binding molecule-mediated ChIP (enChIP) [14] [15] [16] [17] . In iChIP, a locus of interest is tagged by inserting recognition sequences of an exogenous DNA-binding protein such as LexA. The locus is then isolated by affinity purification using the tagged DNA-binding protein. In enChIP, engineered DNA-binding molecules, such as zinc-finger proteins, transcription activator-like (TAL) proteins, and clustered regularly interspaced short palindromic repeats (CRISPR) complexes, are used to tag a locus of interest (Figure 1) . Subsequently, the genomic region is isolated by affinity purification of the tagged DNA-binding molecules.
One of the advantages of enChIP over iChIP is that insertion of recognition sequences of an exogenous DNA-binding protein is not necessary. Targeting of loci using CRISPR complexes consisting of a catalytically inactive form of Cas9 (dCas9) and a guide RNA (gRNA) is much easier than targeting of these regions by iChIP or enChIP using TAL and zinc-finger proteins. Here, we describe a step-by-step protocol for enChIP combined with mass spectrometry and RNA sequencing (RNA-Seq) to identify locus-associated proteins and RNAs, respectively.
Protocol

Design of Engineered DNA-binding Molecules Recognizing the Target Locus
1. For enChIP using CRISPR complexes, use the CRISPRdirect web tool (http://crispr.dbcls.jp) to identify candidate gRNA target sequences in the genomic region of interest described as previously 18 . This web tool returns 23 bp genomic sites of the form 5'-N 20 NGG-3' within the target region. 2. Synthesize a gBlock including the U6 promoter sequence and the sequence of 5'-N 20 in 5'-N 20 NGG-3' using commercial services (see Figure  2 ) 19, 20 . For subcloning purposes, include appropriate restriction enzyme sites outside of the gBlock. 3. Insert the gBlock into an appropriate vector as previously described
Establishment of Cells for the enChIP Analysis
1. Express 3×FLAG-dCas9 and the gRNA (CRISPR-based procedure) or 3×FLAG-TAL (TAL protein-based procedure) in the cells to be analyzed as described previously [14] [15] [16] [17] . 1. Use transient transfection if the transfection efficiency is high. An expression vector containing 3×FLAG-dCas9 and the CMV promoter is available (see Materials). 2. Consider establishing stable transformants using conventional methods if the transient transfection efficiency is low. In addition to the aforementioned retroviral vectors for gBlock, retroviral vectors of 3×FLAG-dCas9 are available (see Materials).
2. Confirm the expression of the 3xFLAG-dCas9 or 3xFLAG-TAL protein in the transfected cells by immunoblot analysis using an anti-FLAG antibody (Ab) as described previously [14] [15] [16] [17] . Note: Expression of these tagged proteins can also be confirmed by intracellular staining with anti-FLAG-FITC and a subsequent FACS analysis. A protocol for intracellular staining can be downloaded from our homepage (http://www.biken.osaka-u.ac.jp/lab/microimm/fujii/ iChIP_protocols/english.html). 16 . Add 50 mg of light or heavy L-Lysine-2HCl and LArginine-HCl in 500 ml of medium. 2. Trypsinize and replate cells before they become confluent so that cells maintain exponential growth. Rotate at 4 °C for 1 hr. 3. Place the tube on a magnet stand and wait for 3 min. 4. Transfer the supernatant into the tube in which Protein G-conjugated magnetic beads conjugated with anti-FLAG Ab were prepared. Rotate at 4 °C O/N. 5. Place the tube on a magnet stand and wait for 3 min. Discard the supernatant by pipetting. 6. Suspend the beads in 1 ml of low salt buffer (20 mM Tris (pH 8.0), 2 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 1x protease inhibitors) and rotate at 4 °C for 5 min. Place the tube on a magnet stand and wait for 3 min. Discard the supernatant by pipetting and repeat the wash step. 7. Wash the beads with high salt buffer (20 mM Tris (pH 8.0), 2 mM EDTA, 500 mM NaCl, 1% Triton X-100, 0.1% SDS, and 1x protease inhibitors) twice. 8. Wash the beads with LiCl buffer (10 mM Tris (pH 8.0), 1 mM EDTA, 250 mM LiCl, 0.5% IGEPAL CA-630, 0.5% sodium deoxycholate, and 1x protease inhibitors) twice. 9. Wash the beads with TBS-IGEPAL CA-630 (50 mM Tris (pH 7.5), 150 mM NaCl, 0.1% IGEPAL CA-630, and 1x protease inhibitors) once. 10. Suspend the beads in 200 µl of elution buffer (50 mM Tris (pH 7.5), 150 mM NaCl, 0.1% IGEPAL CA-630, 1x protease inhibitors, and 500 µg/ ml 3×FLAG peptide) and incubate at 37 °C for 20 min. Place the tube on a magnet stand and wait for 3 min. Transfer the supernatant into a new 1.5 ml tube and repeat the elution step. 11. Purify DNA from small portion (e.g., 5%) of the eluate by phenol-chloroform extraction or by using a DNA extraction kit (see Materials). The purified DNA can be used for PCR with specific primer sets to estimate the yields of enChIP analyses by comparing with input DNA prepared in Step 6.7 as described previously 14, 16 .
Crosslinking of Cells with Formaldehyde
SDS-PAGE, Staining, and Mass Spectrometric Analysis
1. Mix the eluate (400 µl) with 1 ml of 2-propanol, 50 µl of 3M sodium acetate (pH 5.2), and 5 µl of 20 mg/ml glycogen. Precipitate the chromatin at -20 °C O/N. 2. Centrifuge the sample (16,000 × g at 4 °C for 30 min) and discard the supernatant. Rinse the pellet with 1 ml of 70% ethanol and centrifuge again (16,000 × g at 4 °C for 10 min). Discard the supernatant completely by pipetting. 3. Suspend the pellet in 40 µl of 2x sample buffer (125 mM Tris (pH 6.8), 10% 2-mercaptoethanol, 4% SDS, 10% sucrose, and 0.004% bromophenol blue). Vortex for 5 min to dissolve the pellet completely, and then incubate at 100 °C for 30 min to denature the proteins and reverse the crosslinking. 4. For SDS-PAGE, run 40 µl of the sample on the gel until the dye reaches 1 cm below the well. Note: We usually use 4-20% gradient gels, but other % gels can be used. 5. Stain the gel with Coomassie Brilliant Blue or silver stain. 6. Cut the gel into five pieces (2 mm height). 7. Perform in gel digestion and mass spectrometric analysis as described previously 15, 16 . .
Categories Proteins
Mammalian telomere-binding proteins PML, RPA, CDK1, PARP1, PCBP1
Telomere-binding proteins in yeast or other organisms
IMP4
Proteins interacting with telomere-binding proteins [associated telomere-binding protein]
Proteins localizing to heterochromatin BEND3
Proteins regulating epigenetic marks KDM5C
Proteins whose mutations affect telomere function DNA polymerase α (POLA1), HAT1, Nup133, CDK7, DPOE1, PRDX1, TYSY, glutamate-cysteine ligase, glutaredoxin, SMRC1 
Discussion
Here, we describe the purification of specific genomic regions using engineered DNA-binding molecules such as the CRISPR system and TAL proteins, and the identification of proteins and RNAs bound to these genomic regions. Binding of engineered DNA-binding molecules to the genome may affect chromatin structure, including nucleosome positioning, and may abrogate genomic functions, as described in CRISPR interference experiments 21 . To avoid these potential aberrant effects, we propose specific guidelines for choosing target genomic regions. First, to avoid potential inhibition of the recruitment of RNA polymerases and transcription factors, as well as disruption of nucleosome positioning around the transcription start site, the target regions for analyses of promoter regions should be several hundred base pairs upstream of (5' to) the transcription start site. By contrast, when analyzing genomic regions with distinct boundaries, such as enhancers and silencers, genomic regions that are directly juxtaposed to these regions can be targeted because it is less likely that the binding of engineered DNA-binding molecules will affect their functions. Furthermore, it is best to avoid using target regions that are conserved among different species, because important DNA-binding molecules often bind to evolutionarily conserved regions and inhibition of their binding might disrupt the functions of the target genomic regions. In this regard, it is always necessary to check that the function of the target genomic region is maintained in the established cells used for enChIP analyses. Because multiple gRNAs can be tested easily and it is tedious and expensive to generate multiple versions of TAL or zinc-finger proteins recognizing different target genomic regions, enChIP using CRISPR is more advantageous than enChIP using other proteins.
It has been shown that dCas9 binds to off-target sites although affinity to those sites might be weaker than that to the target sites [22] [23] [24] [25] . There are several ways to manage contamination of molecules bound to those off-target sites. First, the use of several, at least two, different gRNAs would be recommended. Those molecules commonly observed in enChIP using distinct gRNAs would be true positives. Second, comparison of different conditions for enChIP would be effective in cancelling contamination of non-specific molecules and molecules bound to off-target sites. Examples of those comparison sets would be (i) stimulation (-) and (+), or (ii) different cell types such as T cells vs. B cells. Finally, quantitative analysis of binding of candidate molecules should be performed to confirm their specific binding to the target sites. It is preferable to prepare cells expressing only dCas9 but not gRNA as a negative control.
Using enChIP analyses, we were able to successfully identify a number of known and novel molecules interacting with specific genomic regions (Tables 1-3) [14] [15] [16] [17] . However, this technique failed to detect some other known proteins interacting with these regions. For example, STAT1 reportedly associates with the IRF-1 promoter upon IFNγ stimulation 8 , but our enChIP-SILAC analysis did not detect STAT1 as a protein induced to interact with this genomic region 16 . In addition, in the enChIP-MS analysis of telomeres, we did not detect shelterin proteins consisting of TRF-1 and TRF-2 15 , which have been shown to interact with telomeres 26 . There are a few potential reasons for these discrepancies. First, the stoichiometry of binding of Stat1 to the IRF-1 promoter might be very low. It is reasonable that enChIP-MS, including enChIP-SILAC, detects proteins that are more abundantly associated with target genomic regions; hence, the analysis of more cells might be necessary to detect these proteins. Increases in the sensitivities of MS instruments would also contribute to the efficient detection of proteins with low stoichiometric binding. Second, some proteins, possibly including Stat1 and shelterins, might be difficult targets for MS analyses. Third, in our analysis of telomere-binding proteins 15 , the 3×FLAG-TAL proteins recognizing telomeres (3×FN-Tel-TAL) might have blocked the binding of shelterins to telomeres in a competitive fashion.
In contrast to the relative difficulty of detecting transcription factors binding to specific genomic regions using enChIP, we successfully identified epigenetic regulators such as histone modification enzymes using enChIP analyses. The success of this technique may be due to the fact that epigenetic regulators bind to a broad range of genomic regions; hence, more proteins per genomic region are available for MS. Because epigenetic regulators are increasingly recognized as important targets for drugs against intractable diseases such as cancer, enChIP would be a useful tool for the identification of epigenetic drug targets.
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